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Abstract
Triple negative breast cancer (TNBC) is the most lethal breast cancer subtype. Extended periods of lactation protect against breast
cancer development, but the mechanisms underlying this protection are unknown. We examined the effects of the milk protein
alpha-casein over expression in the triple negative MDA-MB-231 breast cancer cell line. The effects of recombinant alpha-casein
added exogenously to MDA-MB-231 breast cancer cells, and immortalised human fibroblasts were also investigated. We used
transcriptional reporters to understand the signalling pathways downstream of alpha-casein in breast cancer cells and these fibro-
blasts that were activated by breast cancer cells. To extend our findings to the clinical setting, we analysed public gene expression
datasets to further understand the relevance of these signalling pathways in triple negative breast cancer cells and patient samples.
Finally, we used small molecular inhibitors to target relevant pathways and highlight these as potential candidates for the treatment
of TN breast cancer. High levels of alpha-casein gene expression were predictive of good prognosis across 263 TNBC patient
tumour samples. Alpha-casein over expression or exogenous addition reduces cancer stem cell (CSC) activity. HIF-1alpha was
identified to be a key downstream target of alpha-casein, in both breast cancer cells and activated fibroblasts, and STAT transcription
factors to be upstream of HIF-1alpha. Interestingly, HIF-1alpha is regulated by STAT3 in breast cancer cells, but STAT1 is the
regulator of HIF-1alpha in activated fibroblasts. In analysis of 573 TNBC patient samples, alpha-casein expression, inversely
correlated to HIF-1alpha, STAT3 and STAT1. STAT1 and STAT3 inhibitors target HIF-1alpha signalling in activated fibroblasts and
MDA-MB-231 breast cancer cells respectively, and also abrogate CSC activities. Our findings provide an explanation for the
protective effects of lactation in TNBC. Clinical data correlates high alpha-casein expression with increased recurrence-free survival
in TNBC patients. Mechanistically, alpha-casein reduces breast cancer stem cell activity in vitro, and STAT3 and STAT1 were
identified as regulators of pro-tumorigenic HIF-1alpha signalling in breast cancer cells and fibroblasts respectively.
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Abbreviations
TNBC Triple negative breast cancer
CAF Cancer associated fibroblast
BCSC Breast cancer stem cell
TME Tumour microenvironment
RFS Recurrence free survival
ER Estrogen receptor
PR Progesterone receptor
Background
Breast cancer is the most common malignancy, and the big-
gest cancer-related killer of women worldwide [1]. Risk fac-
tors such as early menarche, late menopause, and late first
pregnancy (after 30) are all associated with an increase in
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breast cancer risk [2–4]. Inversely, early first pregnancy, mul-
tiple births and extended periods of lactation confer a reduced
risk of developing breast cancer [5]. Notably, the protective
effects of lactation are most profound in the aggressive triple
negative subgroup [2, 3, 6], but the physiological reasons for
this phenomenon remain unclear.
Triple negative breast cancer (TNBC), as defined by the
lack of estrogen (ER), progesterone receptors (PR) and low
expression of HER2 receptor [7] is the most lethal breast can-
cer, and there are currently no convincing targeted therapies
[8] By definition, TNBC is not treatable by common
targeted anti-cancer drugs, as they lack the receptors ca-
pable of responding to them. A signature of this subgroup
is an enrichment for CD24+/ CD44+ and ALDH1 [9, 10],
which confer a breast cancer stem cell phenotype [11].
Breast cancer stem cells (BCSC) are a small population
of cells that reside within the tumour mass that are capa-
ble of self-renewal, but also to repopulate all the cell
types within the heterogeneous tumour mass [12, 13].
BCSC possess increased tumour initiating properties and
metastatic potential [14]. BCSC are proposed to be re-
sponsible for the chemotherapy resistance and lethal me-
tastasis associated with TNBC, and the targeting of such
cells is a promising strategy in its treatment.
Another factor important in tumour progression is the tu-
mour microenvironment (TME). One of the most abundant
cell types in the TME are fibroblasts, which become ‘activat-
ed’ by surrounding cancer cells to acquire a ‘cancer associated
fibroblast’ (CAF) phenotype [15, 16]. CAFs are phenotypical-
ly different to their normal fibroblast counterparts, and are
defined by expression of alpha-smooth muscle actin (alpha-
SMA) and fibroblast activation protein-alpha (FAP-alpha)
[17, 18]. CAFs promote cancer progression by providing se-
cretory factors that promote migration and invasion [19, 20],
and to promote the BCSC phenotype [21].
Extended periods of lactation are protective against
TNBC. The milk protein alpha-casein was shown to re-
duce tumour burden and experimental lung metastasis
when over expressed in mouse Met-1 tumour cells (22).
In the present study, we assessed the effects of alpha-
casein on BCSC activity in vitro and found alpha-casein
to significantly reduce BCSC in the triple negative MDA-
MB-231 cell line. Mechanistically, we showed this activ-
ity to be mediated by HIF-1alpha, a hypoxia inducible
transcription factor closely associated with the induction
and maintenance of a BCSC phenotype [23–25]. We fur-
ther investigated the effects of alpha-casein on the TME
and show alpha-casein to also regulate HIF-1alpha signal-
ling in CAFs. We identified STAT3 and STAT1 to be
crucial transcription factors in regulating HIF-1alpha in
breast cancer stem cells and CAFs respectively, and used
inhibitors to demonstrate their roles in HIF-1alpha regu-
lation and CSC activity.
Methods
Cell Lines and Culture
The human MDA-MB-231 mammary tumour cells were ob-
tained from ATCC (ATCC® HTB-26™). The human hTERT
immortalised human fibroblasts (BJ1) were obtained from
CLONTECH Laboratories (CCD00309196). Cell lines were
passaged for <25 passages and regularly checked for myco-
plasma. Cells were cultured in complete DMEM (Sigma-
Aldrich) supplemented with 10% heat inactivated foetal bo-
vine serum, 2mMGlutaMAX (L-alanyl-L-glutamine), 100 U/
ml Penicillin and 100 μg/ml Streptomycin and incubated at
37 °C with 5% CO2. All incubations performed at 37 °C with
5% CO2.
Stable Cell Line Generation
All stable cell lines were generated using lentiviral transduc-
tion. Alpha-casein (EX-S0252-Lv105) and empty vector con-
trol (EX-NEG-Lv105) expression plasmids were purchased
from GeneCopoeia. Lentiviral particles were produced using
the Lenti-Pac HIVexpression Packaging kit and 293Ta pack-
aging cells both obtained from GeneCopoeia as per manu-
facturers’ instructions, and viral supernatant was used to
infect target cells. Pre-made Cignal™Lenti reporter con-
structs purchased from Qiagen and used to infect target
cells to generate stable reporter cell lines as per the man-
ufacturer’s instructions. These reporter constructs consist
of a luciferase reporter gene fused to the applicable tran-
scriptional response element (TRE) for each signalling
pathway (details Table 1), and are used to quantitatively
measure changes in signalling pathway activation in re-
sponse to different stimuli. Two days following infection,
successfully transduced cells were selected for using
2 μg/ml Puromycin or 1 mg G418 Geneticin® for
14 days.
Production of Conditioned Media
2 × 104 cells / cm3 were cultured in 7.5 ml/ cm3 of low serum
(Nu-serum) media for 48 H. media was collected and centri-
fuged to remove debris and supernatant collected.
Western Blotting
Primary Antibodies Human alpha-casein antibody F20.14
(Abcam ab47972). STAT1 #9172, Phospho-STAT1 (Tyr
701) #9167, Phospho-STAT3 (Tyr 705) #9131 purchased
from Cell Signalling (1:1000). β-actin loading control
(Sigma-Aldrich A2228) (1:10000).
Cell lysates were collected using RIPA lysis buffer (Sigma-
Aldrich) with cOmplete ULTRA protease inhibitor (Roche)
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and PhosSTOP (Roche) phosphatase inhibitor. 20 μg protein
sample was loaded onto 12% polyacrylamide gel and trans-
ferred to nitrocellulose membranes. Membrane was blocked
in 5% bovine serum albumin for 1 h at room temperature and
then probedwith primary antibody, diluted 1:1000 in blocking
solution, and incubated at 4 °C overnight. Anti-mouse or anti-
rabbit secondary antibodies (1:500) were added and incubated
at room temperature for 1 h. Protein was detected using
SuperSignal™West Pico or SuperSignal™West Dura chemi-
luminescent Substrate (ThermoFisher) and developed on
Kodak film.
Mammosphere Assay
Non-adherent mammosphere culture plates were made by
covering clear 6 well plates with 2 ml poly-HEMA and
incubated at 60 °C for 3 days. Cells were syringed
through a 25 gauge needle to provide cells in single cell
suspension. A 1:1 volume of Trypan blue was used to
count viable cells, and 5 × 103 single cells added to each
well in DMEM/F-12 (Sigma-Aldrich) with B27 supple-
ment, 20 ng/ml EGF and 100 U/ml Penicillin and
100 μg/ml Streptomycin. Plates were then incubated for
5 days, and spheres >50 μM counted at 10 x magnifica-
tion. The mammosphere formation efficiency (MFE) was
calculated by dividing the number of spheres >50 μM
after 5 days by the number of cells seeded, and is
expressed as a percentage.
ALDEFLUOR™ Assay
2 × 105 cells were incubated with or without drug treatment
for 48 h. 2 × 105 were re-suspended in 1 ml Dublecco’s PBS.
Dry Aldefluor reagent was reconstituted as per manufacturers’
instructions. 5 μl Aldefluor reagent was added and 500 μl
sample removed and added to a fresh eppendorf tube contain-
ing 10 μl DEAB to stop the reaction. This is the control sam-
ple. Cells were then incubated at 37 °C, 5% CO2 for 40 min,
and centrifuged at 4 °C. Cell pellets were then re-suspended in
500 μl Aldefluor assay buffer and analysed using the BD
Laser Fortessa cell analyser (Biosciences).
Luciferase Reporter Assays
5 × 103 reporter cells were seeded in triplicate in 96 well black
plates and incubated overnight. Culture mediumwas removed
and cells washed with PBS, and 100 μl control media, condi-
tioned media or drug treatment was then added. Plates were
then incubated for 24, 48 or 72 h as per experimental design.
Reporter cells were fluorescently labelled to normalise lucif-
erase activity. Following fluorescence reading, cells were
lysed and luciferase activity measure using the Promega lucif-
erase system and read on a IVIS® luminometer
(PerkinElmer).
PrestoBlue™ Proliferation
1 × 104 cells per well were seeded in triplicate in 96 well black
plates, and incubated for 8 h for cells to adhere. 20 μl
PrestoBlue® reagent was added and incubated for 1 h and
fluorescence (excitation 544 nm, emission 621–10 nm) mea-
sured using a FLUOstart Omega microplate reader (BMG
Labtech) for T = 0 timepoint. Further plates are incubated for
24, 48 and 72 h, and fluorescence measured as before.
Fluorescence readings were normalised by T = 0 h.
Transwell Migration Assay
5 × 104 cells were added to the top of 8 μM pore cell culture
inserts (Transwells) (Falcon) placed in 24-well plates in
serum-free media. Cells were allowed to migrate through the
membrane for 6 h at 37 °C, towards 10% foetal bovine serum
placed in the bottom wells to serve as chemoattractant. Non-
invasive cells were removed from the top of the wells using
cotton swabs, and migrated cells stained with crystal violet
solution. After 20 min, wells were washed in H20 and mem-
branes left to dry overnight. The number of migrated cells was
calculated using a bright-field microscope, where the number
of cells in six fields of view per membrane (20x objective)
were counted. An average number was calculated over 3 in-
dependent experiments, in duplicate, carried out on indepen-
dent days.
Table 1 Transcriptional response elements used in luciferase reporter constructs
Reporter construct Pathway Transcription factor TRE
Cignal lenti ISRE reporter (luc) CLS-008 L Type I IFN STAT1/STAT2 TAGTTTCACTTTCCC
Cignal lenti GAS reporter (luc) CLS-009 L Type II IFN STAT1/STAT1 AGTTTCATATTACTCTAAATC
Cignal lenti STAT3 (luc) CLS-6028 L STAT3 STAT3 GTCGACATTTCCCGTAAATCGTCGA
Cignal lenti NF-κB (luc) CLS-013 L NF-κB NF-κB GGGACTTTCC
Cigna lenti HIF-1α (luc) CLS-007 L Hypoxia HIF-1α TACGTGCT
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Statistical Methods
All graphs were produced in Graphpad Prism 7, and this soft-
ware was used for statistical analysis. Data are shown using
the standard error of the mean (±SEM), taken over 3 biolog-
ical replicates with 2 or 3 technical replicates. Statistical sig-
nificance was calculated using parametric testing, assuming
equal variance, with un-paired Student’s t test used to confirm
statistical significance. Statistical significance was governed
as a p value < = 0.05. Gene expression levels of alpha-casein
signalling genes were retrieved from 17 Affymetrix datasets
integrated to remove batch effects as previously described
[26]. Similarly, Affymetrix gene expression data from three
breast cancer cell line panel studies were integrated as de-
scribed previously [26]. Cox proportional hazards survival
analysis was performed for all possible points-of-separation
(low–high cut-off points) for each gene (Pearce DA, Nirmal
AJ, Freeman TC, Sims AH. Continuous biomarker assess-
ment by exhaustive survival analysis. bioRxiv 2017. doi:
https://doi.org/10.1101/208660). Gene expression levels of
alpha-casein between normal and invasive ductal carcinoma
were explored with dataset GSE10780 [27].
Results
Alpha-Casein Expression Correlates with Improved
Clinical Outcome in Triple Negative Breast Cancer,
and Reduces Breast Cancer Stem Cell Activity In Vitro
Firstly, we observed that that alpha-casein expression in inva-
sive ductal carcinomas is significantly lower than in normal
breast duct tissue (Fig. 1a). We then used a compendium of
integrated published gene expression analysis datasets to in-
vestigate the relationship of alpha-casein expression to
relapse-free survival (RFS) in over 250 triple negative breast
cancer patient samples. All possible cut-points were consid-
ered, with 45/261 significantly (p < 0.05) associating lower
alpha-casein expression levels with worse outcomes in terms
of relapse-free survival (Fig. 1b). To elucidate the mechanisms
for the observed clinical data, we generated stable MDA-MB-
231 cell lines over expressing alpha-casein (using lentiviral
transduction and selection). Stable empty vector (EV) cell
lines were generated as a control. It has previously been
shown that alpha-casein reduces tumour growth and metasta-
sis in vivo [22]. However, we found no effect on proliferation
and migration in MDA-MB-231 cells (supplementary
Figure 1 A&B). In order to test another mechanism to explain
the in vivo results, we examined stem cell activity by assaying
mammosphere formation. Figures 1 B&F.i show that alpha-
casein expression reduces the mammosphere formation effi-
ciency (MFE) of breast cancer cells by nearly half compared
to EV control cells. Addition of purified alpha-casein at a
concentration of 500 μg/ml also produced a strong inhibition
of MFE (Fig. 1d). We wanted to examine if these effects were
replicated in other TNBC cell lines, and show that alpha-
casein inhibits MFE of MDA-MB-453 cells (Fig. 1e&f.ii)
indicating that alpha-casein is not just protective in the
MDA-MB-231 TNBC cell line. These in vitro findings are
supported by the patient data presented in Fig. 4. However,
alpha-casein did not affect MFE in the SUM149 triple nega-
tive breast cancer cells (Supplementary Figure 1D), showing
that alpha-casein is not protective in all TNBC cell lines. The
reasons for resistance to alpha-casein in the SUM149 TNBC
cell line would require further investigation.
Next, we tested the effect of alpha-casein overexpression
on ALDH enzyme activity using the Aldefluor assay. This has
previously reported to be a marker of breast cancer stem cells,
and predicts for poor clinical outcome [28]. alpha-casein over-
expression reduces the population of ALDH positive cells by
nearly half (Fig. 1f). These results suggest the anti-
tumourigenic effects of alpha-casein in vivo [22] may partly
be explained by the ability of alpha-casein to inhibit cancer
stem cell activity.
Alpha-Casein Functions Mechanistically to Target
pro-Tumorigenic HIF-1alpha Signalling in Breast
Cancer Cells and Fibroblasts
We next wanted to investigate the cellular signalling mecha-
nisms responsible for the inhibitory effects of alpha-casein on
BCSC activity. HIF-1alpha stabilisation and upregulation pro-
motes and maintains the BCSC phenotype via multiple mech-
anisms (Mathieu et al, 2011; Schwab et al, 2012; Zhang et al,
2016). NF-kB is a second well -established signalling path-
way that is upregulated in breast cancer, and known to regu-
late SC activity (Iliopoulos et al, 2009; Iliopoulos et al, 2011;
Rinkenbaugh and Baldwin, 2016; Shostak and Chariot, 2011).
Thus, we sought to investigate alpha-casein effects on these
key CSC signalling pathways in breast cancer.
Stable HIF-1alpha and NF-κB-promoter-luciferase re-
porter constructs were transduced into MDA-MB-231 cells
using lentiviral transduction. MDA-MB-231 breast cancer
cells were cultured with purified alpha-casein (versus BSA
as a control) for up to 72 h, and changes in cell signalling
monitored. We show that alpha-casein inhibits HIF-1alpha
signalling in MDA-MB-231 cells in a dose- dependent
manner, and by greater than half after 72 h (Fig. 2a), but
had no effect on NF-κB signalling (Supplementary
figure 1C). We used a similar lentiviral approach as above
to generate reporter fibroblast cell lines to study the poten-
tial effects of breast cancer cells, and HIF-1alpha signals in
the microenvironment. Hyperactivation of HIF-1alpha sig-
nalling in fibroblasts is a signature of adoption of a
tumour-promoting CAF phenotype [20, 29–31]. We found
that breast cancer cells activate HIF-1alpha in fibroblasts
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(Fig. 2b and c), an effect that is inhibited back to, or below
basal levels following addition of alpha-casein. This sug-
gests that alpha-casein is able to prevent the pro-
tumourigenic ‘activation’ of fibroblasts induced by breast
cancer cells. Thus, HIF-1alpha, but not NFκβ, is a key
downstream target of alpha-casein but the mechanism for
its activation is unknown. We note that fibroblasts are not
exposed to milk proteins in intact homeostatic mammary
tissue but envisage that in the context of mammary
remodelling during lactation, weaning and involution, the
fibroblasts will be exposed to milk that builds up in the
ducts and leaks into the tumour microenvironment.
Alpha-Casein Inhibits STAT3 and STAT1 in Breast
Cancer Cells and Fibroblasts Respectively
STAT3 is a strong candidate for HIF-1alpha regulation in
breast cancer cells. Previous studies in breast cancer cells
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Fig. 1 Alpha-casein expression
correlates with improved
clinical outcome in triple
negative breast cancer, is lower
expressed in cancer tissue and
reduces breast cancer stem cell
activity in vitro. a The
expression level of alpha-casein is
significantly (p = 7e-6) higher in
normal breast ducts than invasive
ductal cancer (IDC). b Gene ex-
pression analysis of 262 triple
negative breast cancer patient
samples shows that alpha-casein
expression correlates with RFS
over 15 years follow-up (p =
0.03). c Alpha-casein expression
reduces the mammosphere for-
mation efficiency (MFE) of triple
negative breast cancer cells
(MDA-MB-231) by 0.62 fold
compared to empty vector (EV)
control cells. d 500 μg/ml of pu-
rified alpha-casein applied exog-
enously reduces the ability of
MDA-MB-231 cells and eMDA-
MB-453 triple negative breast
cancer cells to form spheres. All
n = 9. f Representative images of
spheres after 5 days in non-
adherent culture f.i alpha-casein
expression versus empty vector
control in MDA-MB-231 cells.
f.ii 500 μg/ml alpha casein re-
duces the abilty ofMDA-MB-453
cells to form spheres. g Alpha-
casein expression reduces the
population of bright ALDH posi-
tive MDA-MB-231 cells by 0.6
fold over an average of 3 inde-
pendent experiments, in dupli-
cate, compared to EV control. n =
6. All * p < p.05, ****p < 0.0001
vs controls
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showed that STAT3 can regulate transcription of HIF-1alpha
target genes directly [32], but that STAT3 and HIF-1alpha also
work cooperatively to regulate HIF-1alpha target genes via the
formation of an ‘enhansome complex’ with CREB binding
protein and p300 [32].
To test this hypothesis, STAT3-luciferase reporter MDA-
MB-231 cells were cultured with conditioned media collected
from control EVor alpha-casein overexpressing MDA-MB231
cells. Alpha-casein conditioned media reduces STAT3 reporter
activity in breast cancer cells by greater than half, indicating less
STAT3 activation (Fig. 3a). This was confirmed by western blot
analysis which demonstrated 50% less STAT3 phosphorylation
(Fig. 3b). We found no effect on STAT3 activity in fibroblasts
(data not shown). In contrast, we identified STAT1 as the
signalling molecule upregulated in fibroblasts (Fig. 3 C&D),
but that its activation was inhibited by alpha-casein (Fig. 3
c&d). Both the transcriptional and phosphorylation analyses
establish that the targets of alpha-casein over expression are
different in breast cancer cells compared to stromal fibroblasts.
Alpha-Casein Expression Inversely Correlates
with STAT1, STAT3 and HIF-1alpha in Basal Breast
Cancer
To confirm that alpha-casein signalling is relevant to all basal
breast cancers, we considered expression of STAT1, HIF-1
alpha and STAT3 across three integrated breast cancer cell line
panel datasets. Note that alpha-casein was not detectably
a MDA-MB-231
CM - +    +    +    +    +    +    +
b
c
BJ1 ﬁbroblastsFig. 2 Alpha-casein functions
mechanistically to target pro-
tumorigenic HIF-1alpha signal-
ling in breast cancer cells and
CAFs. a Alpha-casein reduces
HIF-1alpha signalling in MDA-
MB-231 cells by greater than half
after 72 h in a dose dependent
manner. b Conditioned media
collected from MDA-MB-231
cells activates HIF-1alpha signal-
ling in fibroblasts. Alpha-casein
reduces this activation back to, or
below basal levels at 48 and 72 h.
c Representative images of biolu-
minescence data from b shown.
All n = 9 *p < 0.05, ** p < 0.01,
*** p < 0.001, **** p < 0.0001 vs
reporter alone controls
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expressed across any of the cell lines. In accordance with our
in vitro findings, the heatmap and boxplots in Fig. 4a demon-
strate that HIF1-alpha, STAT3 and STAT1 have increased ex-
pression in the basal (TNBC) and claudin-low compared to the
luminal breast cancer cell lines when comparing 83 different
cell lines, 37 of which are triple-negative. This suggests this is
a phenomenon across multiple triple-negative breast cancer
subtypes. We next analysed the correlation between these
genes and alpha-casein expression in TNBC patients.
Analysis of 573 triple negative samples revealed that alpha-
casein expression is significantly, inversely correlated with
HIF-1alpha, STAT3 and STAT1 (Fig. 4b) (p < 0.0001),
suggesting the relevance of alpha-casein signalling in TNBC
in the clinical setting.
a
c
d
MDA-MB-231
BJ1 ﬁbroblasts
BJ1 ﬁbroblasts
MDA-MB-231bFig. 3 Alpha-casein inhibits
STAT3 and STAT1 in breast
cancer cells and fibroblasts
respectively. a Conditioned
media collected from alpha-
casein over expressing MDA-
MB-231 cells reduces STAT3
signalling in wild-type (WT) cells
by greater than half n = 9. * p <
0.05, *** p < 0.001, **** p <
0.0001, vs reporter with condi-
tioned media collected from EV
control cells. b The activation of
STAT3, as measured by the
abundance of phospho-STAT3
(Tyr-705) was examined by
western blot. 500 μg/ml alpha-
casein reduces STAT3 activation
in MDA-MB-231 cells by an av-
erage of 0.6 fold over 2 indepen-
dent experiments. n = 2. c
Conditioned media collected
from MDA-MB-231 cells acti-
vates Type II IFN signalling in
fibroblasts, as measured by acti-
vation of the STAT1 GAS lucif-
erase reporter. Alpha-casein re-
duces this activation back to, or
below, basal eves after 72 h. n = 9.
** p < 0.01, *** p < 0.001, ****
p < 0.0001 vs reporter plus con-
ditioned media d STAT1 activa-
tion was examined by western
blot with an antibody directed
against its active, phosphorylated
form (Tyr- 701). 500μg/ml alpha-
casein inhibits the activation of
STAT1 in fibroblasts by breast
cancer cell conditioned media.
Average of 2 independent experi-
ments shown in bottom quadrant.
n = 2. **** p < 0.0001 vs control
media
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STAT3 and STAT1 Function Upstream of HIF-1alpha
in Breast Cancer Cells and Fibroblasts Respectively
After identifying STAT3 and STAT1 to be potential can-
didates for HIF-1alpha regulation in breast cancer cells
and fibroblasts, we next investigated their direct effect
on HIF-1alpha signalling by using small molecule inhib-
itors of the STAT1 and STAT3 transcription factors. The
inhibitors Niclosamide and Fludarabine were functional-
ly active in inhibiting STAT3 and STAT1, respectively
(Supplementary figure 2 A&B respectively). STAT3 and
STAT1 inhibition reduced HIF-1alpha transcriptional ac-
tivity in both breast cancer cells (Fig. 5a) and fibro-
blasts following activation with conditioned media col-
lected from MDA-MB-231 breast cancer cells (Fig. 5b).
These results establish that STAT3 and STAT1 function
upstream of HIF-1alpha in TNBC cells and fibroblast
cells, respectively.
Targeting STAT3 Reduces BCSC Activity
Since STAT3 inhibition strongly abrogated HIF1-alpha sig-
nalling, we tested the effects of Niclosamide on BCSC activity
using colony formation and ALDH activity. Niclosamide
treatment significantly inhibited the MFE (%) of MDA-MB-
231 cells by up to 70% at the highest concentration (Fig. 5c &
d). In addition, Niclosamide almost completely abolished
ALDH activity in MDA-MB-231 cells (Fig. 5e). Therefore,
we propose a model whereby alpha-casein acts directly on
breast cancer stem cells, but also stromal cells of the tumour
microenvironment by targeting HIF-1alpha (Fig. 6). Alpha-
casein inhibits STAT3 activity in breast cancer cells upstream
of HIF-1alpha, which leads to a reduction in BCSC activity.
Alpha casein also inhibits STAT1 in CAFs which reduces pro-
tumourigenc HIF-1alpha signalling in these cells. The inhibi-
tion of CSC activity of breast cancer cells by alpha-casein will
further reduce tumorigenicity by abrogating the pro-
a Gene expression levels across three integrated breast cell line datasets. 
Blue= Luminal, Red=Basal A, Yellow=Claudin-low, orange= Basal B , purple=HER2
b Triple negave breast cancer paent gene expression  data  (N= 573 TN samples)
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Fig. 4 alpha-casein expression
inversely correlates with STAT3
and HIF-1alpha in basal breast
cancer. a Heatmap and boxplots
showing that HIF-1alpha, STAT1
and STAT3 are upregulated in
triple negative and claudin-low
breast cancer datasets using un-
supervised clustering of 500 most
variable genes in 3 integrated
breast cancer cell line datasets. b
Inverse correlation of HIF-1alpha,
STAT1 and STAT3 versus alpha-
casein expression (CSNS1) in
573 TNBC patient samples (All p
< 0.0001)
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tumuiogenic bi-directional interaction between cancer stem
cells and stromal neighbouring cells.
Discussion
TNBC is the most aggressive breast cancer subtype, and is
associated with poor clinical outcome. A major factor
governing this lethality is the propensity of TNBC to recur
following chemotherapy [33, 34], metastasise [35, 36], and
the lack of targeted therapy. One of the major factors respon-
sible for this chemotherapy resistance, and thus high recur-
rence rates in TNBC is the enrichment of BCSC, particularly
in this subtype [9, 10]. Furthermore, chemotherapy, which is
the current mainstay treatment for TNBC, has been shown to
further enrich for cells with a BCSC phenotype [37, 38], with
the activation of the hypoxia inducible factor HIF-1alpha be-
ing key in this response [39].
The inhibitory effects of the milk protein alpha-casein on
mouse mammary tumour burden and experimental lung me-
tastasis in vivo have previously been described [22]. There are
a number of possible explanations why extended lactation
could be protective, for example, limiting the exposure of
the breast to the inflammatory environment of involution, or
preventing potentially pre-cancerous cells from proliferating.
If lactation is having a protective effect, it must be preventing
transformation from normal to pre-cancerous cell, progression
from pre-cancerous to tumour cell, or preventing growth and
metastasis of the tumour. In this study, we have modelled the
final lethal stage, where acquisition of a CSC phenotype pro-
motes invasion and metastasis and provided functional expla-
nation for these findings, where alpha-casein disrupts the CSC
c
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DMSO control
5 μM Niclosamide
MDA-MB-231
MDA-MB-231 CAFs
+DMSO                  + 5μM Niclosamide +DMSO              + 2μM              +10 μM
Fludarabine
bFig. 5 STAT3 and STAT1function upstream of HIF-
1alpha in breast cancer cells
and fibroblasts respectively. a
The STAT3 inhibitor Niclosamide
inhibits HIF-1alpha signalling in
MDA-MB-231 cells. b Similarly,
the STAT1 inhibitor Fludarabine
inhibits HIF-1alpha signalling in
fibroblasts. cNiclosamide inhibits
the MFE of MDA-MB-231 breast
cancer cells by nearly half. All
n = 9. d Representative image of
spheres after 5 days in non-
adherent culture. e Niclosamide
almost completely abolished the
percentage of bright ALDH posi-
tive MDA-MB-231 cells. n = 6.
All ** p < 0.01, **** p < 0.0001
vs DMSO control
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activity ofMDA-MB-231 TNBC cells. In future studies it will
therefore be important to test the effects of casein on earlier
stages of progression.
A role of HIF-1alpha in the propagation and maintenance
of this CSC phenotype has been reported [23, 24, 40], and this
study further supports these ideas. We investigated the effects
of alpha-casein on HIF-1alpha activation and signalling and
found it to inhibit HIF1-alpha in TNBC cells, and that STAT3
is a regulator of HIF-1alpha signalling in this context.We used
small molecule inhibitors of STAT3 to show its importance in
the activation of HIF-1alpha in TNBC cells and downstream
BCSC activity, where STAT3 and HIF-1alpha inhibition re-
sults in a > 70% reduction in CSC characteristics. STAT3 has
previously been implicated in the promotion of CSC activity
in hepatocellular carcinoma via activation of the Notch signal-
ling pathway [21]. Herein we have found an alternative mech-
anism of STAT3 mediated CSC activation in breast cancer,
where STAT3 phosphorylation at Y705 and concurrent acti-
vation increases BCSC via HIF-1alpha.
Interestingly, alpha-casein also inhibits HIF-1alpha signal-
ling in fibroblasts that have been activated by breast cancer
cells, but the mechanism of regulation is via a different STAT
transcription factor in these cells, STAT1. As the adoption of
this CAF phenotype via HIF-1alpha serves to promote cancer
progression by providing metabolites and nutrients to energy-
demanding cancer cells [41, 42] and promoting a CSC pheno-
type [23, 24, 40], alpha-casein may also function via a
feedforward inhibition of HIF-1alpha. Here, inhibition of
HIF-1alpha signalling decreases the CSC activity, propagation
and invasiveness of breast cancer cells, which in turn reduces
CAFs in the surrounding stroma.
Thus, alpha-casein has a dual role on inhibiting breast can-
cer progression. We propose a mechanism (Fig. 6) whereby
alpha-casein directly inhibits the CSC activity of transformed
breast cancer cells via inhibition of STAT3 and HIF-1alpha.
Alpha-casein also inhibits HIF-1alpha in CAFs to abrogate the
pro-tumorigenic reciprocal relationship between CAFs and
BCSCs and ultimately cancer progression and metastasis.
Conclusion
We have provided mechanistic evidence as to how extended
periods of lactation can potentially protect against TNBC. In
the present study, we describe a new role of the milk protein
alpha-casein as a negative regulator of CSC activity and
transformation to a CAF phenotype in TNBC via HIF-
1alpha (Fig. 6). This work indicates that targeting STAT1
and STAT3 using small molecule drugs could be beneficial
to patients in the clinic.
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